StoneWise, a China-based pharmaceutical company that uses AI to accelerate drug discovery, has raised an aggregate USD100m in funding through its Series B and B+ rounds. Legend Capital led the Series B, while Lightspeed China and Greater Bay Area Homeland Investments led the Series B+. New investors CDH VGC and Eastern Bell Capital participated in the rounds and existing investors GL Ventures, SIG, Long Hill Capital and Linear capital followed on. Read more